<DOC>
	<DOCNO>NCT00282087</DOCNO>
	<brief_summary>The purpose trial study benefit give chemotherapy woman surgical resection primary disease evidence disease remain ( know adjuvant therapy ) . The major objective study determine progression free survival . The goal prevent relapse recurrence uterine leiomyosarcoma .</brief_summary>
	<brief_title>Adjuvant Chemotherapy High Risk Uterine Leiomyosarcoma</brief_title>
	<detailed_description>Patients diagnosis early-stage uterine leiomyosarcoma 70 % chance relapse recurrence disease . Patients enrol trial receive 4 cycle gemcitabine docetaxel follow 4 cycle adriamycin . Following completion chemotherapy , repeat image regular interval monitor disease recurrence along periodic clinical evaluation .</detailed_description>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>≥ 18 year age high risk uterine LMS , FIGO stage I II pathology review LMS high grade /or mitotic rate great equal 5 mitoses/10 hpf longer 12 week surgical resection cancer evidence residual disease ECOG 0 1 ANC ≥ 1,500 , hemoglobin ≥ 8.0 , platelet ≥100,000 creatinine ≤ 1.5 x institutional upper limit normal adequate liver function neuropathy ( sensory motor ) ≤ CTC grade 1 negative pregnancy test sign consent patient invasive malignancy prior therapy gemcitabine docetaxel doxorubicin hypersensitivity reaction docetaxel drug formulate polysorbate 80 woman breast feeding cardiac ejection fraction &lt; 50 % prior pelvic irradiation treatment hormone replacement antihormonal agent cytotoxic agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>early stage</keyword>
	<keyword>high grade</keyword>
	<keyword>uterine leiomyosarcoma</keyword>
	<keyword>adjuvant treatment</keyword>
</DOC>